{
    "clinical_study": {
        "@rank": "129458", 
        "arm_group": [
            {
                "arm_group_label": "Celiac Disease Alone Gluten Challenge", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Celiac Disease Alone Sham Challenge", 
                "arm_group_type": "Sham Comparator"
            }, 
            {
                "arm_group_label": "Celiac Disease and T1D Gluten Challenge", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Celiac Disease and T1D Sham Challenge", 
                "arm_group_type": "Sham Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the immune response causing celiac disease\n      is related to the autoimmune response causing type-1 diabetes."
        }, 
        "brief_title": "Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes", 
        "condition": [
            "Type 1 Diabetes", 
            "Celiac Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Celiac Disease", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "Participants meeting eligibility criteria will have blood collected before and after a\n      three-day oral gluten challenge. This blood will be tested for biomarkers associated with\n      islet autoimmunity and gluten-specific cellular immunity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Celiac Disease by histology and serology\n\n          -  For those with Type-1 Diabetes, at least one anti-islet antibody\n\n          -  HLA-DQ2.5 genotype\n\n        Exclusion Criteria:\n\n          -  Not following a gluten free diet for at least 12 months\n\n          -  Known gluten exposure within the prior 2 months\n\n          -  Treatment with systemic immune modifying biological agents (adalimumab, etanercept,\n             infliximab, certolizumab pegol) in prior 6 months\n\n          -  Treatment with systemic immunomodulatory agents in prior 30 days\n\n          -  Human immunodeficiency virus infection, untreated hepatitis B virus, or hepatitis C\n             virus infection\n\n          -  Nut allergy\n\n          -  Hemoglobin level below normal range\n\n          -  History of angina\n\n          -  Pregnant or lactating\n\n          -  Severe symptoms to gluten challenge in the past\n\n          -  Elevation in transglutaminase-IgA or deamidated gliadin peptide IgA or IgG greater\n             than or equal to 50% above upper limit of normal\n\n          -  Uncontrolled complications of type-1 diabetes or celiac disease which pose a risk to\n             participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932476", 
            "org_study_id": "GC001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Celiac Disease Alone Gluten Challenge", 
                    "Celiac Disease and T1D Gluten Challenge"
                ], 
                "description": "Three-day gluten containing dietary challenge.", 
                "intervention_name": "Gluten Challenge", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Celiac Disease Alone Sham Challenge", 
                    "Celiac Disease and T1D Sham Challenge"
                ], 
                "description": "Three-day sham (gluten free) dietary challenge", 
                "intervention_name": "Sham Challenge", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "contact": {
                "email": "david.baidal@joslin.harvard.edu", 
                "last_name": "David Baidal, MD", 
                "phone": "888-813-8669"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02215"
                }, 
                "name": "Joslin Diabetes Center"
            }, 
            "investigator": {
                "last_name": "Jason Gaglia, MD, MMSc", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomized Double-Masked Gluten Challenge to Evaluate Markers of Autoimmunity in Patients With Type-1 Diabetes and Celiac Disease After Oral Gluten Challenge", 
        "overall_contact": {
            "email": "sarah.szubowicz@joslin.harvard.edu", 
            "last_name": "Sarah Szubowicz, MPH", 
            "phone": "617-309-4493"
        }, 
        "overall_official": {
            "affiliation": "Joslin Diabetes Center", 
            "last_name": "Jason Gaglia, MD, MMSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood samples for markers of autoimmunity will be taken before and day 3 post challenge.", 
            "measure": "Change in Markers of Autoimmunity", 
            "safety_issue": "No", 
            "time_frame": "Baseline and day 3 post challenge"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932476"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Joslin Diabetes Center", 
            "investigator_full_name": "Jason Gaglia", 
            "investigator_title": "Assistant Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Gastrointestinal symptoms are recorded in a standardized diary at baseline and for 6 days inclusive of challenge.", 
            "measure": "Gastrointestinal Symptoms", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and 6 days"
        }, 
        "source": "Joslin Diabetes Center", 
        "sponsors": {
            "collaborator": {
                "agency": "ImmusanT, Inc.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Joslin Diabetes Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}